Current Report Filing (8-k)
09 May 2018 - 8:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 4, 2018
SYNEOS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36730
|
|
27-3403111
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
3201 Beechleaf Court, Suite 600, Raleigh, North Carolina 27604-1547
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (919) 876-9300
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(e)
|
Letter Agreement with Jason Meggs, Chief Financial Officer
|
The Board of Directors (the
Board) of Syneos Health, Inc. (the Company) appointed Jason Meggs as Chief Financial Officer of the Company effective May 6, 2018.
Mr. Meggs was serving as Executive Vice President and Interim Chief Financial Officer since February 21, 2018, and has been the
Companys principal financial officer and principal accounting officer since that time.
In connection with his appointment, the
Company entered into a letter agreement effective May 6, 2018 with Mr. Meggs (the Letter Agreement) that, among other things, modified his employment agreement as follows: (i) increased his annual base salary to $475,000,
(ii) increased his annual target bonus opportunity to 70% of his base salary, and (iii) included him as a participant in the Companys Executive Severance Plan, as adopted by the Board on September 15, 2016.
The Company intends to file a copy of the Letter Agreement as an exhibit to the Companys next regularly scheduled quarterly report on
Form
10-Q
for the fiscal quarter ended March 31, 2018.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SYNEOS HEALTH, INC.
|
|
|
|
Date: May 8, 2018
|
|
|
|
/s/ Purvesh D. Patel
|
|
|
|
|
Name:
|
|
Purvesh D. Patel
|
|
|
|
|
Title:
|
|
Executive Vice President and Interim General Counsel and Corporate Secretary
|
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024